- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01549769
Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes
February 1, 2024 updated by: Reata, a wholly owned subsidiary of Biogen
A Multiple-Dose, Open-Label Pharmakokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes
This study is to evaluate the pharmacokinetics and pharmacodynamics of bardoxolone methyl in patients with chronic kidney disease and type 2 diabetes.
Study Overview
Status
Terminated
Intervention / Treatment
Detailed Description
Study Sponsor, originally Reata Pharmaceuticals, Inc., is now Reata Pharmaceuticals, Inc., a wholly owned subsidiary of Biogen.
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Screening eGFR ≥ 15.0 and < 45.0 mL/min/1.73 m2.
- A history of type 2 diabetes; diagnosis should have been made at ≥ 30 years of age (if diabetes developed at a younger age, a fasting C-peptide level must confirm type 2 diabetes);
- Male or female patients at least 18 years of age;
- Body mass index (BMI) between 18.5 and 45 kg/m2;
- Treatment with an angiotensin converting enzyme (ACE) inhibitor and/or an angiotensin II receptor blocker (ARB) for at least 6 weeks prior to Study Day -1. The dosage of ACE inhibitor and/or ARB must be stable for 2 weeks prior to Screening (i.e., no change in dosage or medication). Patients not taking an ACE inhibitor and/or ARB, or taking an ACE inhibitor and/or ARB at levels below the goal dose set by K/DOQI guidelines (see Appendix B) must have a documented medical contraindication (e.g., hyperkalemia, hypotension), which the investigator must provide and discuss with a medical monitor prior to Study Day -1. Patients not taking an ACE inhibitor and/or ARB because of a medical contraindication must have discontinued treatment at least 8 weeks prior to Screening;
- Mean systolic blood pressure (SBP) must be ≤ 160 mmHg and ≥ 105 mmHg and mean diastolic blood pressure (DBP) must be ≤ 90 mmHg during screening;
- Willing to practice methods of birth control (both males who have partners of childbearing potential and females of childbearing potential) from screening through Study Day 84;
- Female patients of childbearing potential must be non-pregnant and non-lactating and have a negative serum pregnancy test result prior to enrollment in the study;
- Willing and able to give written informed consent for study participation;
- Willing and able to cooperate with all aspects of the protocol;
Exclusion Criteria:
- Type 1 diabetes mellitus (juvenile onset). If a history of diabetic ketoacidosis exists, a fasting C-peptide level must confirm type 2 diabetes;
- History of a renal transplant or a planned transplant from a living donor during the study;
- Hemoglobin A1c level > 11.0% (97 mmol/mol) during screening;
- Acute dialysis or acute kidney injury within 24 weeks prior to Study Day -1;
- Clinical signs and/or symptoms of uremia and expected need for renal replacement therapy within 12 weeks following Study Day -1, as assessed by the investigator;
- Albumin/creatinine ratio (ACR) > 3500 mg/g during screening;
Recently active cardiovascular disease defined as:
- Unstable angina pectoris within 12 weeks before Study Day -1;
- Myocardial infarction, coronary artery bypass graft surgery, or percutaneous transluminal coronary angioplasty/stent within 12 weeks before Study Day -1;
- Cerebrovascular accident, including transient ischemic attack within 12 weeks before Study Day -1;
- Current diagnosis of Class III or IV NYHA congestive heart failure (Appendix C);
- Clinical diagnosis of severe obstructive valvular heart disease or severe obstructive hypertrophic cardiomyopathy;
- Atrioventricular block, 2° or 3°, not successfully treated with a pacemaker;
- Diagnostic or interventional procedure that required a contrast agent that may induce nephropathy within 30 days prior to Study Day -1, or planned during the study;
- Systemic immunosuppression for more than 15 days , cumulatively, within the 12 weeks prior to Study Day -1, or anticipated need for immunosuppression during the study;
- Total bilirubin, aspartate transaminase (AST), or alanine transaminase (ALT) level greater than the upper limit of normal (ULN) or alkaline phosphatase level greater than two times the ULN on ANY screening laboratory test result;
- Iron saturation < 20% on Study Day -1. If iron saturation is < 20% at screening, iron supplements may be provided prior to Study Day -3;
- Serum magnesium levels < 1.3 mEg/L (0.65 mmol/L) on Study Day -1. If serum magnesium levels are < 1.3 mEg/L (0.65 mmol/L) at screening, oral magnesium replacement may be provided prior to Study Day -3;
- Known hypersensitivity to any component of the study drug;
- Current history of drug or alcohol abuse, as assessed by the investigator;
- Clinically significant infection requiring intravenous administration of antibiotics or hospitalization within 6 weeks prior to Study Day -1;
- Donation or receipt of blood or blood components within the 4 weeks prior to Study Day -1. The investigator should instruct patients who participate in this study not to donate blood or blood components for 4 weeks after the completion of the study;
- Abnormal ECG at screening, which is interpreted by the investigator to be clinically significant;
- Use of tobacco-containing products (e.g., cigarettes, cigars, chewing tobacco, snuff, etc.) or products for smoking cessation 2 weeks prior to Study Day -1;
- Treated with any investigational agent within 30 days before Study Day -1, 5 half-lives, or twice the duration of biological effect of the previous investigational drug (whichever is longer);
- A clinical condition that, in the judgment of the investigator, could potentially pose a health risk to the patient while involved in the study;
- Participation in a clinical study involving any intervention within 30 days prior to Study Day -1, concurrent participation in such a study, or participation in a prior clinical study involving bardoxolone methyl in any form;
- Unable to communicate or cooperate with the investigator due to language problems, poor mental development or impaired cerebral function.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bardoxolone Methyl 20 mg
|
Oral, once daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the curve
Time Frame: 24 hours
|
24 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to maximum observed concentration
Time Frame: 56 days
|
56 days
|
Area under the plasma concentration-time curve
Time Frame: 0 to last observed concentration
|
0 to last observed concentration
|
Maximum observed concentration
Time Frame: 56 days
|
56 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 30, 2012
Primary Completion (Actual)
November 30, 2012
Study Completion (Actual)
October 31, 2013
Study Registration Dates
First Submitted
March 6, 2012
First Submitted That Met QC Criteria
March 8, 2012
First Posted (Estimated)
March 9, 2012
Study Record Updates
Last Update Posted (Actual)
February 2, 2024
Last Update Submitted That Met QC Criteria
February 1, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Glucose Metabolism Disorders
- Metabolic Diseases
- Urologic Diseases
- Endocrine System Diseases
- Disease Attributes
- Chronic Disease
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Kidney Diseases
- Renal Insufficiency, Chronic
- Renal Insufficiency
Other Study ID Numbers
- 402-C-1102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationRecruitingType 2 Diabetes Mellitus With ComplicationIndia
Clinical Trials on Bardoxolone Methyl
-
Reata, a wholly owned subsidiary of BiogenCompleted
-
Reata, a wholly owned subsidiary of BiogenCompleted
-
Reata, a wholly owned subsidiary of BiogenWithdrawnDiabetes Mellitus, Type 2 | Renal Insufficiency, Chronic
-
Reata, a wholly owned subsidiary of BiogenCompletedHealthy | Hepatic ImpairmentUnited States
-
Reata, a wholly owned subsidiary of BiogenWithdrawnDiabetes Mellitus, Type 2 | Renal Insufficiency, Chronic
-
Reata, a wholly owned subsidiary of BiogenTerminatedChronic Kidney Diseases | Autosomal Dominant Polycystic Kidney | Alport SyndromeUnited States, France, Australia, Japan, Spain, Puerto Rico
-
Reata, a wholly owned subsidiary of BiogenCompletedDiabetic NephropathyUnited States
-
Reata, a wholly owned subsidiary of BiogenCompletedDiabetes Mellitus, Type 2 | Renal Insufficiency, ChronicUnited States
-
Reata, a wholly owned subsidiary of BiogenWithdrawn
-
Kyowa Kirin Co., Ltd.TerminatedDiabetic Kidney DiseaseJapan